CSF1R-expressing TAMs may exert stronger tumor-promoting immunity in never-smoking patients than in ever-smoking patients; therefore, never-smokers with lung adenocarcinoma may be particularly responsive to CSF1R-targeted therapies. The gene discussed is CSF1R; the disease is lung adenocarcinoma.